Találati lista | Tudóstér

001-es BibID:

BIBFORM090883

Első szerző:

Cím:

Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

ISSN:

0160-2446

Megjegyzések:

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -

További szerzők:

Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Egyéb kapcsolat (1)

Borító:

Saját polcon:

001-es BibID:

BIBFORM090869

035-os BibID:

(cikkazonosító)e19

Első szerző:

Papp Zoltán (kardiológus, élettanász)

Cím:

Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero

Dátum:

2020

Megjelenés:

Utánközlés / Másodközlés

ISSN:

2057-7540 2057-7559

Megjegyzések:

Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use

Tárgyszavak:

Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk

Megjelenés:

Cardiac Failure Review. - 6 (2020), p. 1-16. -

További szerzők:

Internet cím:

Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat

Lásd még:

Utánközlés (1)

Borító:

Saját polcon:

001-es BibID:	BIBFORM040618
Első szerző:	Papp Zoltán (kardiológus, élettanász)
Cím:	Levosimendan : molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan / Papp Z., Édes I., Fruhwald S., De Hert S. G., Salmenperä M., Leppikangas H., Mebazaa A., Landoni G., Grossini E., Caimmi P., Morelli A., Guarracino F., Schwinger R. H., Meyer S., Algotsson L., Wikström B. G., Jörgensen K., Filippatos G., Parissis J. T., González M. J., Parkhomenko A., Yilmaz M. B., Kivikko M., Pollesello P., Follath F.
Dátum:	2012
Megjegyzések:	The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal of Cardiology. - 159 : 2 (2012), p. 82-87. -
További szerzők:	Édes István (1952-) (kardiológus) Fruhwald, Sonja De Hert, Stefan G. Salmenperä, Markku Leppikangas, Heli Mebazaa, Alexandre Landoni, Giovanni Grossini, Elena Caimmi, Philippe Morelli, Andrea Guarracino, Fabio Schwinger, Robert H. G. Meyer, Sven Algotsson, Lars Wikström, Gerhard Jörgensen, Kirsten Filippatos, Gerasimos S. Parissis, John González, Martín J. Parkhomenko, Alexander Yilmaz, Mehmet Birhan Kivikko, Matti Pollesello, Piero Follath Ferenc
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM114410
035-os BibID:	(scopus)85169671684
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period : The multinational randomized trial / Pölzl Gerhard, Altenberger Johann, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-González Martín Jesús, Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Maier Sarah, Vrtovec Bojan, Wikström Gerhard, Zima Endre, Bauer Axel, LeoDOR Investigators
Dátum:	2023
ISSN:	1388-9842 1879-0844
Megjegyzések:	Aim: The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF). Methods and results: In this prospective multicentre, double-blind, two-armed trial, patients with advanced HF were randomized 2:1 at the end of an index hospitalization for acute HF to intermittent levosimendan therapy or matching placebo for 12 weeks. All patients had left ventricular ejection fraction (LVEF) ?30% during index hospitalization. Levosimendan was administered according to centre preference either as 6 h infusion at a rate of 0.2 ?g/kg/min every 2 weeks, or as 24 h infusion at a rate of 0.1 ?g/kg/min every 3 weeks. The primary efficacy assessment after 14 weeks was based on a global rank score consisting of three hierarchical groups. Secondary clinical endpoints included the composite risk of tiers 1 and 2 at 14 and 26 weeks, respectively. Due to the COVID-19 pandemic, the planned number of patients could not be recruited. The final modified intention-to-treat analysis included 145 patients (93 in the combined levosimendan arm, 52 in the placebo arm), which reduced the statistical power to detect a 20% risk reduction in the primary endpoint to 60%. Compared with placebo, intermittent levosimendan had no significant effect on the primary endpoint: the mean rank score was 72.55 for the levosimendan group versus 73.81 for the placebo group (p = 0.863). However, there was a signal towards a higher incidence of the individual clinical components of the primary endpoint in the levosimendan group versus the placebo group both after 14 weeks (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.12-7.68; p = 0.021) and 26 weeks (HR 1.64, 95% CI 0.87-3.11; p = 0.122). Conclusions: Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Heart Failure. - 25 : 11 (2023), p. 2007-2017. -
További szerzők:	Altenberger, Johann Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Maier, Sarah Vrtovec, Bojan Wikström, Gerhard Zima Endre (1974-) (kardiológus) Bauer, Axel LeoDOR Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM090865
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period / Pölzl Gerhard, Allipour Birgani Shadab, Comín-Colet Josep, Delgado Juan F., Fedele Francesco, Garcia-Gonzáles Martín J., Gustafsson Finn, Masip Josep, Papp Zoltán, Störk Stefan, Ulmer Hanno, Vrtovec Bojan, Wikström Gerhard, Altenberger Johann
Dátum:	2019
ISSN:	2055-5822
Megjegyzések:	Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	ESC heart failure. - 6 : 1 (2019), p. 174-181. -
További szerzők:	Allipour Birgani, Shadab Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Garcia-González, Martín J. Gustafsson, Finn Masip, Josep Papp Zoltán (1965-) (kardiológus, élettanász) Störk, Stefan Ulmer, Hanno Vrtovec, Bojan Wikström, Gerhard Altenberger, Johann
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM070106
Első szerző:	Pölzl, Gerhard
Cím:	Repetitive use of levosimendan in advanced heart failure : need for stronger evidence in a field in dire need of a useful therapy / Pölzl Gerhard, Altenberger Johann, Baholli Loant, Beltrán Paola, Borbély Attila, Comin-Colet Josep, Delgado Juan F., Fedele Francesco, Fontana Antonella, Fruhwald Friedrich, Giamouzis Gregory, Giannakoulas George, Garcia-González Martín J., Gustafsson Finn, Kaikkonen Kari, Kivikko Matti, Kubica Jacek, von Lewinski Dirk, Löfman Ida, Malfatto Gabriella, Manito Nicolás, Martínez-Sellés Martin, Masip Josep, Merkely Bela, Morandi Fabrizio, Mølgaard Henning, Oliva Fabrizio, Pantev Emil, Papp Zoltán, Perna Gian Piero, Pfister Roman, Piazza Vito, Bover Ramón, Rangel-Sousa Diego, Recio-Mayoral Alejandro, Reinecke Alexander, Rieth Andreas, Sarapohja Toni, Schmidt Gunter, Seidel Mirko, Störk Stefan, Vrtovec Bojan, Wikström Gerhard, Yerly Patrik, Pollesello Piero
Dátum:	2017
ISSN:	0167-5273
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal Of Cardiology. - 243 (2017), p. 389-395. -
További szerzők:	Altenberger, Johann Baholli, Loant Beltrán, Paola Borbély Attila (1978-) (kardiológus) Comin-Colet, Josep Delgado, Juan F. Fedele, Francesco Fontana, Antonella Fruhwald, Friedrich Giamouzis, Gregory Giannakoulas, George Garcia-González, Martín J. Gustafsson, Finn Kaikkonen, Kari Kivikko, Matti Kubica, Jacek von Lewinski, Dirk Löfman, Ida Malfatto, Gabriella Manito, Nicolás Martínez-Sellés, Martin Masip, Josep Merkely Béla (1965-) (orvos) Morandi, Fabrizio Mølgaard, Henning Oliva, Fabrizio Pantev, Emil Papp Zoltán (1965-) (kardiológus, élettanász) Perna, Gian Piero Pfister, Roman Piazza, Vito Bover, Ramón Rangel-Sousa, Diego Recio-Mayoral, Alejandro Reinecke, Alexander Rieth, Andreas Sarapohja, Toni Schmidt, Gunter Seidel, Mirko Störk, Stefan Vrtovec, Bojan Wikström, Gerhard Yerly, Patrik Pollesello, Piero
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM070112
Első szerző:	Seferović, Petar M.
Cím:	Organization of heart failure management in European Society of Cardiology member countries : survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups / Seferović Petar M., Stoerk Stefan, Filippatos Gerasimos, Mareev Viacheslav, Kavoliuniene Ausra, Ristić Arsen D., Ponikowski Piotr, McMurray John, Maggioni Aldol, Ruschitzka Frankl, van Veldhuisen Dirk J., Coats Andrew, Piepoli Massimo, McDonagh Theresa, Riley Jillian, Hoes Arno, Pieske Burkert, Dobrić Milan, Papp Zoltan, Mebazaa Alexandre, Parissis John, Ben Gal Tuvia, Vinereanu Dragos, Brito Dulce, Altenberger Johann, Gatzov Plamen, Milinković Ivan, Hradec Jaromír, Trochu Jean-Noel, Amir Offer, Moura Brenda, Lainscak Mitja, Comin Josep, Wikström Gerhard, Anker Stefan, Committee of National Heart Failure Societies or Working Groups of the Heart Failure Association of the European Society of Cardiology
Dátum:	2013
ISSN:	1388-9842
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Heart Failure. - 15 : 9 (2013), p. 947-959. -
További szerzők:	Stoerk, Stefan Filippatos, Gerasimos S. Mareev, Vyacheslev Kavoliuniene, Ausra Ristić, Arsen D. Ponikowski, Piotr McMurray, John J. Maggioni, Aldo Ruschitzka, Frank van Veldhuisen, Dirk J. Coats, Andrew Piepoli, Massimo McDonagh, Theresa Riley, Jillian Hoes, Arno Pieske, Burkert Dobrić, Milan Papp Zoltán (1965-) (kardiológus, élettanász) Mebazaa, Alexandre Parissis, John Ben Gal, Tuvia Vinereanu, Dragos Brito, Dulce Altenberger, Johann Gatzov, Plamen Milinković, Ivan Hradec, Jaromír Trochu, Jean-Noel Amir, Offer Moura, Brenda Lainscak, Mitja Comin-Colet, Josep Wikström, Gerhard Anker, Stefan D. Committee of NHFS or WGHFA of the ESC
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: